477 related articles for article (PubMed ID: 18391573)
21. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
[TBL] [Abstract][Full Text] [Related]
22. Sublingual immunotherapy.
Esch RE
Curr Opin Otolaryngol Head Neck Surg; 2008 Jun; 16(3):260-4. PubMed ID: 18475082
[TBL] [Abstract][Full Text] [Related]
23. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study.
Marogna M; Bruno ME; Massolo A; Falagiani P
Eur Ann Allergy Clin Immunol; 2008 May; 40(1):22-9. PubMed ID: 18700331
[TBL] [Abstract][Full Text] [Related]
24. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care.
de Bot CM; Moed H; Berger MY; Röder E; Hop WC; de Groot H; de Jongste JC; van Wijk RG; Bindels PJ; van der Wouden JC
Pediatr Allergy Immunol; 2012 Mar; 23(2):150-8. PubMed ID: 22017365
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.
Di Lorenzo G; Mansueto P; Pacor ML; Rizzo M; Castello F; Martinelli N; Ditta V; Lo Bianco C; Leto-Barone MS; D'Alcamo A; Di Fede G; Rini GB; Ditto AM
J Allergy Clin Immunol; 2009 May; 123(5):1103-10, 1110.e1-4. PubMed ID: 19356792
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis.
Mun SJ; Shin JM; Han DH; Kim JW; Kim DY; Lee CH; Min YG; Rhee CS
Int Forum Allergy Rhinol; 2013 Mar; 3(3):177-83. PubMed ID: 23044892
[TBL] [Abstract][Full Text] [Related]
27. [The results of extra diagnostic methods in patients allergic to dust mites treated by specific immunotherapy].
Modrzyński M; Mazurek H; Zawisza E
Przegl Lek; 2005; 62(12):1337-42. PubMed ID: 16786743
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of sublingual immunotherapy.
Scadding G; Durham S
J Asthma; 2009 May; 46(4):322-34. PubMed ID: 19484663
[TBL] [Abstract][Full Text] [Related]
29. The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus.
Tsai JJ; Liao EC; Tsai FH; Hsieh CC; Lee MF
J Asthma; 2009 Mar; 46(2):165-70. PubMed ID: 19253124
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis.
Lee JE; Choi YS; Kim MS; Han DH; Rhee CS; Lee CH; Kim DY
Ann Allergy Asthma Immunol; 2011 Jul; 107(1):79-84. PubMed ID: 21704889
[TBL] [Abstract][Full Text] [Related]
31. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy.
Marcucci F; Sensi L; Di Cara G; Salvatori S; Bernini M; Pecora S; Burastero SE
Pediatr Allergy Immunol; 2005 Sep; 16(6):519-26. PubMed ID: 16176400
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
[TBL] [Abstract][Full Text] [Related]
34. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites.
Passalacqua G; Pasquali M; Ariano R; Lombardi C; Giardini A; Baiardini I; Majani G; Falagiani P; Bruno M; Canonica GW
Allergy; 2006 Jul; 61(7):849-54. PubMed ID: 16792583
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice.
Ferrés J; Justicia JL; García MP; Muñoz-Tudurí M; Alvà V
Allergol Immunopathol (Madr); 2011; 39(3):122-7. PubMed ID: 20570032
[TBL] [Abstract][Full Text] [Related]
36. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
[TBL] [Abstract][Full Text] [Related]
37. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
38. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
39. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment.
de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC
BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864
[TBL] [Abstract][Full Text] [Related]
40. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting.
Marogna M; Spadolini I; Massolo A
Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):135-42. PubMed ID: 15916014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
